Capella Columns
RSolv Capella HPLC Columns are the perfect solution for high-performance liquid chromatography applications. Designed to deliver consistent and reliable results, our Capella columns offer exceptional separation efficiency across a diverse range of sample types
RSolv Capella Columns are designed to meet the diverse requirements of analytical and preparative chromatography with a variety of stationary phases:
- C18: The gold standard for most reverse-phase applications, offering exceptional performance and versatility.
- C8, C6, C4: Ideal for applications requiring moderate hydrophobic interactions.
- Phenyl: Tailored for aromatic compounds, providing enhanced selectivity.
- PFP (Pentafluorophenyl): Perfect for combining polar and hydrophobic interactions.
- CN (Cyanopropyl):Excels in separating polar compounds and mixtures with high selectivity.
- AMINO: Specifically suited for basic analytes requiring targeted interactions.
- DIOL: Optimized for chiral separations and effective across a wide range of compound classes.
- Silica: Delivers the highest resolution and selectivity for normal-phase chromatography.This comprehensive range ensures precise and efficient separations for a variety of chromatographic applications
.jpg)
Phases | Feature |
---|---|
Propyl (C3) | Propyl phase separates Polar Compounds, NeutralCompounds and Protein |
HTS (C12) | Separates biological compounds based on adamantane |
Cyclohexyl (C6H12) | Separates Aromatic Compounds |
Fluorooctyl (C8H16F5) | Specifically designed for the separation of fluorinated compounds, isomers and positional isomers combination compounds |
Fluoropropyl (C3H6F5) | Primarily used for separation of fluorinated compounds |
Technical Specifications:
pH Range: 2.0-8.0
Pore Size: 60Å, 100Å, 125Å(Custom Req),300Å
Particle Size (μm): 1.8 (Length: 30 to 150), 3.0, 5.0,10.0 (Length: 50 to 250)
Surface area: 325 m²/g
Length: 30, 50, 100, 150 and 250
Dimension: 2.1, 3.0, 4.0 and 4.6
Application: Tazobactum, Rufinamide, Sulfadiazine, Tafamidis meglumine and Acalabrutinib
